BTK and mantle cell lymphoma: Therefore, the finding that ibrutinib-resistant cells exhibit constitutive activation of the AKT pathway is consistent with a role for AKT in resistance mechanisms and overall support the combination use of BTK and PI3K/AKT pathway inhibitors in MCL.